Retatrutide lowered A1C and body weight more than semaglutide 2 mg in the first head-to-head diabetes trial comparing the two treatments, according to topline results announced by Eli Lilly on October 28, 2026. The findings offer an early look at how an investigational triple-action medicine compares with the active ingredient in Ozempic.
But the retatrutide vs. Ozempic A1C study also raises questions about tolerability, interpretation, and what the results mean outside a clinical trial. More participants receiving retatrutide stopped treatment because of side effects, and retatrutide remains investigational and not FDA approved.
Here is what TRANSCEND-T2D-2 reported, how to understand the numbers, and why the findings are promising without being the final word.
What Was the Retatrutide vs. Ozempic Study?
The head-to-head trial, called TRANSCEND-T2D-2 and registered as NCT06260722, enrolled 1,298 adults with type 2 diabetes. It compared retatrutide with semaglutide 2 mg over 80 weeks.
Semaglutide is the active ingredient in Ozempic. Describing the trial as retatrutide versus Ozempic is therefore useful shorthand, but the precise comparison matters: these results concern the semaglutide 2 mg comparator studied in this trial, not every semaglutide dose or formulation.
The study was open-label, meaning participants and investigators knew which treatment participants received. That does not make the results invalid, but it is an important design detail when interpreting treatment experiences, discontinuations, and other outcomes.
The available findings come from a Lilly topline announcement, also covered by AJMC. A topline release summarizes major results rather than providing the complete detail needed for a comprehensive independent assessment.
A1C Results: How Much Did Each Treatment Lower Blood Sugar?
Participants began the trial with an average A1C of 8.3%. A1C is a measure used to assess average blood sugar over approximately the preceding two to three months.
At 80 weeks, the reported A1C reductions were:
- Retatrutide 9 mg: a reduction of 2.2 percentage points.
- Retatrutide 12 mg: a reduction of 2.2 percentage points.
- Semaglutide 2 mg: a reduction of 1.8 percentage points.
These dose levels describe the research groups; they are not dosing recommendations.
Understanding the 0.4-Percentage-Point Difference
Both retatrutide groups showed an A1C reduction that was 0.4 percentage points greater than the reduction reported with semaglutide 2 mg.
The wording matters. An A1C change expressed in percentage points is different from a relative percentage reduction. The study reported a 2.2-percentage-point decline with retatrutide, not a 2.2% relative decline.
These are also group-level results, not a prediction of what any particular person would experience. Average changes cannot show the full range of individual responses or establish how many participants reached a particular A1C target without additional data.
Weight Loss Was Greater With Retatrutide
The difference between treatments was larger for body weight. At 80 weeks, the reported average percentage reductions were:
- Retatrutide 9 mg: 19.5%.
- Retatrutide 12 mg: 20.9%.
- Semaglutide 2 mg: 9.4%.
Those figures explain much of the attention surrounding the study. In this trial population, retatrutide produced substantially greater average weight reduction alongside the larger A1C decline.
However, these were adults with type 2 diabetes participating in a defined research protocol. The results should not automatically be applied to people without diabetes, different treatment settings, or other semaglutide regimens.
Why the Two Outcomes Need Separate Interpretation
A1C and body weight measure different aspects of treatment response. Greater weight reduction does not, by itself, establish better long-term diabetes outcomes, and a larger A1C reduction does not answer every question about overall benefit and risk.
The study provides comparative evidence on the reported endpoints. It does not establish that retatrutide prevents more cardiovascular events, kidney complications, or deaths than semaglutide. Those conclusions would require evidence specifically addressing those outcomes.
Side Effects: More Participants Stopped Retatrutide
Tolerability is an important counterweight to the efficacy findings. According to the reported results, the proportions of participants who stopped treatment because of side effects were:
- Retatrutide 9 mg: 4.8%.
- Retatrutide 12 mg: 7.9%.
- Semaglutide 2 mg: 2.7%.
Discontinuation because of side effects was therefore more frequent in both retatrutide groups, particularly the 12 mg group.
These percentages do not represent everyone who experienced a side effect. They describe the narrower group whose side effects led them to stop treatment. They also do not, on their own, explain the severity, duration, or specific nature of those events.
A balanced interpretation includes both efficacy and tolerability. Looking only at the largest A1C or weight change leaves out a meaningful part of the comparison.
How Retatrutide Differs From Ozempic
Retatrutide is an investigational peptide designed to activate three hormone receptors: GIP, GLP-1, and glucagon. It is commonly described as a triple agonist.
Semaglutide acts at the GLP-1 receptor. The treatments therefore differ in their receptor targets, even though both are being discussed here in relation to blood sugar and weight.
Retatrutide’s three-receptor design provides a biological rationale for studying it. However, the number of receptors a medicine targets does not automatically establish that it is safer or better. Comparative clinical evidence, rather than the mechanism alone, must support those judgments.
Is Retatrutide FDA Approved?
No. Retatrutide remains investigational and is not FDA approved. Positive trial results do not amount to regulatory approval, and this announcement does not make retatrutide an approved substitute for Ozempic.
The findings also should not be treated as evidence that products marketed online as retatrutide are equivalent to the investigational medicine used in the trial. The study results concern the treatment evaluated under the trial protocol.
What the Topline Results Still Cannot Tell Us
The announcement answers an important comparative question, but a fuller evaluation requires more than headline averages. Relevant details include:
- Statistical methods: how the investigators analyzed treatment differences and handled missing data.
- Participant characteristics: whether responses varied across different groups.
- Safety findings: the types, frequency, and seriousness of adverse events.
- Treatment persistence: how stopping treatment affected the analysis.
- Longer-term outcomes: whether the observed changes translate into durable benefits and acceptable risks.
The open-label design also deserves consideration. A1C is a laboratory measurement, but knowing the assigned treatment may influence behavior, expectations, or reporting. Full publication would allow closer examination of how the researchers addressed these issues.
The Bottom Line on Retatrutide vs. Ozempic A1C Results
In TRANSCEND-T2D-2, retatrutide 9 mg and 12 mg each reduced A1C by 2.2 percentage points, compared with 1.8 percentage points for semaglutide 2 mg over 80 weeks. Retatrutide also produced greater average weight reduction, while more participants stopped it because of side effects.
The central finding is stronger reported A1C and weight effects accompanied by a tolerability trade-off. These results are important comparative evidence, but they are not a guarantee of individual outcomes, proof of superior long-term complication prevention, or regulatory approval.
This article is informational coverage of clinical research, not medical advice or guidance on using investigational compounds.
